

**510(k) SUMMARY OF SAFETY AND EFFECTIVENESS  
TightRope™ Acromioclavicular (AC) Device**

**NAME OF SPONSOR:** Arthrex, Inc.  
1370 Creekside Boulevard  
Naples, Florida 34108-1945

**510(K) CONTACT:** Sally Foust, RAC  
Regulatory Affairs Project Manager  
Telephone: (239) 643-5553 ext. 1251  
FAX: (239) 598-5539

**TRADE NAME:** TightRope™ Acromioclavicular (AC)  
Device

**COMMON NAME:** Button/Suture

**DEVICE PRODUCT CODE/CLASSIFICATION:**

HTN: Single/multiple component  
metallic bone fixation appliances and  
accessories:  
21 CFR 888.3030

**PREDICATE DEVICES**

K043248: TightRope Syndesmosis Device (Arthrex, Inc.)  
K023294: Bosworth Coraco-Clavicular Screw and Washer (Howmedica  
Osteonics)  
K041356: Tenodesis Family (Arthrex, Inc.)  
K003227: Bio-Absorbable Corkscrew (Arthrex, Inc.)  
pre-1976, Kirschner (K) Wire (Synthes)

**DEVICE DESCRIPTION AND INTENDED USE**

The TightRope™ Acromioclavicular (AC) Device is designed as two differently sized metal buttons, both stainless steel or both titanium, and FiberWire™ suture. The buttons are pre-threaded with FiberWire suture, looped twice through the buttonholes. Pull-through FiberWire sutures are also looped through each button.

The TightRope™ Acromioclavicular (AC) Device is intended as an adjunct in fracture repair involving metaphyseal and periarticular small bone fragments where screws are not indicated, and as an adjunct in external and intramedullary fixation systems involving plates and rods, with fracture braces and casting.

Specifically, the Arthrex TightRope Acromioclavicular (AC) Device is intended to provide fixation during the healing process following a syndesmotic trauma, such as fixation of acromioclavicular separations due to coracoclavicular ligament disruptions.

#### **SUBSTANTIALLY EQUIVALENCE**

Arthrex has determined that the TightRope™ Acromioclavicular (AC) Device is substantially equivalent to the predicate devices where basic features and intended uses are the same. Any design differences between the Arthrex TightRope™ Acromioclavicular (AC) Device when compared to predicate devices used in the standard medical practice for the treatment of acromioclavicular separations due to coracoclavicular disruptions are considered minor and do not raise any questions concerning safety and effectiveness. Any differences have been found to have no apparent effect on the performance, function, or intended use of the device.



Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Sally Foust, RAC  
Regulatory Affairs Project Manager  
Arthrex, Inc.  
1370 Creekside Boulevard  
Naples, Florida 34108-1945

DEC 13 2005

Re: K052776

Trade/Device Name: TightRope™ Acromioclavicular (AC) Device  
Regulation Number: 21 CFR 888.3030  
Regulation Name: Single/multiple component metallic bone fixation  
appliances and accessories  
Regulatory Class: II  
Product Code: HTN  
Dated: September 28, 2005  
Received: October 3, 2005

Dear Ms. Foust:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



 Mark N. Melkerson  
Acting Director  
Division of General, Restorative  
and Neurological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

**Indications for Use**

510(k) Number (if known): K052776

**Device Name** TightRope™ Acromioclavicular (AC) Device

**Indications for Use:**

The TightRope™ Acromioclavicular (AC) Device is intended as an adjunct in fracture repair involving metaphyseal and periarticular small bone fragments where screws are not indicated, and as an adjunct in external and intramedullary fixation systems involving plates and rods, with fracture braces and casting.

Specifically, the Arthrex TightRope Acromioclavicular (AC) Device is intended to provide fixation during the healing process following a syndesmotic trauma, such as fixation of acromioclavicular separations due to coracoclavicular ligament disruptions.

Prescription Use X  
(Per 21 CFR 801 Subpart D)

AND/OR Over-The-Counter Use \_\_\_\_\_  
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER  
PAGE IF NEEDED)

-----  
Concurrence of CDRH, Office of Device Evaluation (ODE)

Page 1 of 1

  
\_\_\_\_\_  
(Division Sign-Off)

**Division of General, Restorative,  
and Neurological Devices**

510(k) Number K052776